Is tumor bed boost necessary in patients who achieved ypCR following neoadjuvant chemotherapy and breast conserving therapy? (KROG 12-05 and 16-16)

This multi-institutional study intended to investigate the effect of tumor bed boost in patients who achieved pathologic complete response (ypCR) following neoadjuvant chemotherapy (NAC) and breast-conserving therapy (BCT). We identified 180 patients who initially had lymph node (LN) metastasis and...

Full description

Saved in:
Bibliographic Details
Published in:Breast (Edinburgh) 2019-06, Vol.45, p.43-47
Main Authors: Cho, Won Kyung, Park, Won, Choi, Doo Ho, Kim, Yong Bae, Suh, Chang-Ok, Shin, Kyung Hwan, Chie, Eui Kyu, Kim, Jin Ho, Ahn, Seung Do, Kim, Su Ssan, Kim, Kyubo, Kim, Jin Hee, Ahn, Sung Ja, Lee, Sun Young, Lee, Jeongshim, Kim, Sang-Won, Kwon, Jeanny, Ahn, Ki Jung, Shin, Hyun Soo, Lee, Hyung Sik, Lee, Nam Kwon
Format: Article
Language:English
Subjects:
Breast cancer
Neoadjuvant chemotherapy
Radiotherapy
Tumor bed boost
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This multi-institutional study intended to investigate the effect of tumor bed boost in patients who achieved pathologic complete response (ypCR) following neoadjuvant chemotherapy (NAC) and breast-conserving therapy (BCT). We identified 180 patients who initially had lymph node (LN) metastasis and achieved ypCR (ypT0/isN0) following NAC and BCT from the 13 institutions of the Korean Radiation Oncology Group (KROG) 16-16 and KROG 12-05. The effect of tumor bed boost on loco-regional control (LRC), disease-free survival (DFS), and overall survival (OS) rates was analyzed. In all patients, five-year LRC, DFS and OS rates were 97.5%, 95.4%, and 99.4%, respectively. Tumor bed boost was performed in 158 (87.8%) patients. Advanced N-stage (cN2-3, p = 0.036), close resection margin (p 
ISSN:0960-9776
1532-3080
DOI:10.1016/j.breast.2019.02.010